Search Results 1081-1090 of 17068 for monoclonal antibody

1. A Study of the Safety and Effectiveness of GS-5745 in Participants with Moderately to Severely Active Crohn's Disease - Mayo Clinic

   Treatment with any monoclonal antibody within 4 weeks of screening; History or evidence of colonic mucosal dysplasia; HIV, hepatitis B, hepatitis C, or ...

2. A Study of the Safety and Effectiveness of Combined Copaxone and Estriol for Relapsing Remitting Multiple Sclerosis - Mayo Clinic

   Monoclonal antibody; T cell vaccination; Cladribine; Bone marrow transplantation; Azathioprine; Cyclophosphamide; Methotrexate; Mitoxantrone; Cyclosporin ...

3. A Study to Evaluate the Effectiveness and Safety of rAd-IFN Administered With Celecoxib and Gemcitabine in Patients With Malignant Pleural Mesothelioma - Mayo Clinic

   Monoclonal antibody, at least 3 half-lives from last dose;; Non-antibody immunotherapy (e.g., tumor vaccine), at least 42 days from last dose ...

4. Mayo Clinic Minute: How the immune system can make getting an organ transplant trickier

   Bentall says. He says it happens when a person has antibodies that cause their immune system to reject a transplanted organ. "The immune system doesn't ...

5. A Study to Evaluate the Safety, Tolerability, and Determine the Optimal Dose for the Expansion Cohorts of VSV-IFNβ-NIS in Combination with Pembrolizumab in Patients with Refractory Solid Tumors - Mayo Clinic

   Other monoclonal antibodies, antibody-drug conjugates, radioimmunoconjugates, or experimental therapies: ≤4 weeks (≤3 weeks with documented disease ...

6. Myeloma Referral Study (Race, Ethnicity, and Familial Etiologic Relationship, Risk Association, and Linkage Study) - Mayo Clinic

   About this study. The goal of the present study is to answer the question of whether there are clinically relevant subtypes of monoclonal gammopathy of ...

7. Publications - Nadine H. Abdallah, M.D. - Mayo Clinic

   Senescence profiling of monoclonal gammopathies reveals paracrine senescence as a crucial defense against disease progression. Leukemia. 2025 May; 39 (5): ...

8. A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis - Mayo Clinic

   Participation eligibility · History of severe allergic or anaphylactic reactions to monoclonal antibodies or known hypersensitivity to any component of the ...

9. Everolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma - Mayo Clinic

   Patients who have received any continuous or intermittent small molecule therapeutics (excluding monoclonal antibodies) ≤ 5 effective half-lives prior to ...

10. Autoimmune Hemolytic Anemias Clinical Trials - Mayo Clinic Research

    The primary objective of this study is to assess the effectiveness of fostamatinib in subjects with warm antibody autoimmune hemolytic anemia (wAIHA). A Study ...